Synonym
Dazoxiben Free Base; UK37248; UK-37248; UK 37248
IUPAC/Chemical Name
Benzoic acid, 4-(2-(1H-imidazol-1-yl)ethoxy)-
InChi Key
XQGZSYKGWHUSDH-UHFFFAOYSA-N
InChi Code
InChI=1S/C12H12N2O3/c15-12(16)10-1-3-11(4-2-10)17-8-7-14-6-5-13-9-14/h1-6,9H,7-8H2,(H,15,16)
SMILES Code
O=C(O)C1=CC=C(OCCN2C=CN=C2)C=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
to be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Dazoxiben is an antithrombotic agent is a drug that reduces the formation of blood clots.
In vitro activity:
The effect of the thromboxane synthetase inhibitor dazoxiben (UK 37248) on 113Indium-labelled platelet deposition on Dacron arterial grafts was examined in an artificial circulation containing human blood which mimics the haemodynamics of femoropopliteal bypass. The influence of this drug on thromboxane production and platelet reactivity was measured during the experiment. In vitro dazoxiben reduced plasma thromboxane by about 80%. After graft perfusion the mean (± s.e.mean) plasma thromboxane level in the active circuits at 354.3 ±46.3 pg/ml was significantly lower than that in the control circuits of 2013±301 pg/ml (P<0.05) with both post-perfusion circuits having elevated levels compared with the mean pre-circuit value of 79.1±28.7pg/ml (Figure 1).
Reference: Br J Clin Pharmacol. 1983;15 Suppl 1(Suppl 1):61S-65S. https://pubmed.ncbi.nlm.nih.gov/6681706/
In vivo activity:
The effects of pretreatment with the thromboxane synthetase inhibitor UK 37248 (dazoxiben) administered 30 min before intravenous endotoxin (S. enteriditis) in the rat was investigated. UK 37248 pretreatment resulted in a significant (P less than 0.001) decrease in plasma iTXB2 at 30 min and 4 h to 193 +/- 28 pg/ml (n = 5) and 421 +/- 57 pg/ml (n = 5), respectively. Unexpectedly UK 37248 also significantly decreased plasma i6-keto PGF1 alpha at 30 min and 4 h to 360 +/- 75 pg/ml (n = 10) (P less than 0.005) and 1920 +/- 513 pg/ml (n = 10) (P less than 0.05), respectively. UK 37248 significantly (P less than 0.05) reduced the endotoxin mortality rate at 24 h from 69% (n = 13) to 30% (n = 13), UK 37248 also reduced splanchnic infarction from 90% (n = 20) to 6% (n = 16). UK 37248 significantly improved the endotoxin-induced thrombocytopaenia, disseminated intravascular coagulation, hypoglycaemia and lysosomal labilization.
Reference: Br J Clin Pharmacol. 1983;15 Suppl 1(Suppl 1):133S-139S. https://pubmed.ncbi.nlm.nih.gov/6337604/
|
Solvent |
mg/mL |
mM |
| Solubility |
| To be determined |
0.0 |
0.00 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
232.24
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Halushka PV, Cook JA, Wise WC. Beneficial effects of UK 37248, a thromboxane synthetase inhibitor, in experimental endotoxic shock in the rat. Br J Clin Pharmacol. 1983;15 Suppl 1(Suppl 1):133S-139S. doi: 10.1111/j.1365-2125.1983.tb02124.x. PMID: 6337604; PMCID: PMC1427698. 2. Hanson SR, Harker LA. Effect of dazoxiben on arterial graft thrombosis in the baboon. Br J Clin Pharmacol. 1983;15 Suppl 1(Suppl 1):57S-60S. doi: 10.1111/j.1365-2125.1983.tb02108.x. PMID: 6681705; PMCID: PMC1427679.
3. Goldman M, Hall C, Hawker RJ, McCollum CN. Dazoxiben examined for platelet inhibitory effect in an artificial circulation. Br J Clin Pharmacol. 1983;15 Suppl 1(Suppl 1):61S-65S. doi: 10.1111/j.1365-2125.1983.tb02109.x. PMID: 6681706; PMCID: PMC1427697.
In vitro protocol:
1. Goldman M, Hall C, Hawker RJ, McCollum CN. Dazoxiben examined for platelet inhibitory effect in an artificial circulation. Br J Clin Pharmacol. 1983;15 Suppl 1(Suppl 1):61S-65S. doi: 10.1111/j.1365-2125.1983.tb02109.x. PMID: 6681706; PMCID: PMC1427697.
In vivo protocol:
1. Halushka PV, Cook JA, Wise WC. Beneficial effects of UK 37248, a thromboxane synthetase inhibitor, in experimental endotoxic shock in the rat. Br J Clin Pharmacol. 1983;15 Suppl 1(Suppl 1):133S-139S. doi: 10.1111/j.1365-2125.1983.tb02124.x. PMID: 6337604; PMCID: PMC1427698. 2. Hanson SR, Harker LA. Effect of dazoxiben on arterial graft thrombosis in the baboon. Br J Clin Pharmacol. 1983;15 Suppl 1(Suppl 1):57S-60S. doi: 10.1111/j.1365-2125.1983.tb02108.x. PMID: 6681705; PMCID: PMC1427679.
1: Dazoxiben. Lancet. 1983 Mar 19;1(8325):627-8. PMID: 6131306.
2: Reines HD, Halushka PV, Olanoff LS, Hunt PS. Dazoxiben in human sepsis and adult respiratory distress syndrome. Clin Pharmacol Ther. 1985 Apr;37(4):391-5. doi: 10.1038/clpt.1985.60. PMID: 3979000.
3: Tindall H, Tooke JE, Menys VC, Martin MF, Davies JA. Effect of dazoxiben, a thromboxane synthetase inhibitor on skin-blood flow following cold challenge in patients with Raynaud's phenomenon. Eur J Clin Invest. 1985 Feb;15(1):20-3. doi: 10.1111/j.1365-2362.1985.tb00138.x. PMID: 3921380.
4: Luderer JR, Nicholas GG, Neumyer MM, Riley DL, Vary JE, Garcia G, Schneck DW. Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenon. Clin Pharmacol Ther. 1984 Jul;36(1):105-15. doi: 10.1038/clpt.1984.147. PMID: 6428793.
5: Jones EW, Cockbill SR, Cowley AJ, Hanley SP, Heptinstall S. Effects of dazoxiben and low-dose aspirin on platelet behaviour in man. Br J Clin Pharmacol. 1983;15 Suppl 1(Suppl 1):39S-44S. doi: 10.1111/j.1365-2125.1983.tb02105.x. PMID: 6401999; PMCID: PMC1427688.
6: Belch JJ, Cormie J, Newman P, McLaren M, Barbenel J, Capell H, Leiberman P, Forbes CD, Prentice CR. Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: a double-blind trial. Br J Clin Pharmacol. 1983;15 Suppl 1(Suppl 1):113S-116S. doi: 10.1111/j.1365-2125.1983.tb02119.x. PMID: 6337601; PMCID: PMC1427695.
7: Butendieck RR, Murray PM. Raynaud disease. J Hand Surg Am. 2014 Jan;39(1):121-4. doi: 10.1016/j.jhsa.2013.08.117. Epub 2013 Nov 6. PMID: 24211176.
8: Rui YC, Sun DX, Long K. [Effect of dazoxiben on cerebrovascular resistance in rabbits]. Zhongguo Yao Li Xue Bao. 1989 Jul;10(4):342-5. Chinese. PMID: 2624120.
